secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001842952-25-000037
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics doses first patient in Phase 1 trial of CT-95 bispecific antibody
--------------------------------------------------------------------------------

- CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody targeting MSLN-expressing cancers.
- Second TCE bispecific to enter clinic in 2025 following CTIM-76 (Claudin 6 x CD3) earlier this year.
- Phase 1 open-label dose escalation and expansion study for advanced solid tumors (ovarian, pancreatic, lung, mesothelioma).
- Initial data for CT-95 Phase 1 trial expected in mid-2026.
- CEO Martin Lehr highlights expansion of clinical pipeline and leadership in TCE therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295225000037/0001842952-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295225000037/cntx-20250409.htm
  HTML page:      https://secwatch.observer/filing/0001842952-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer